Is Adaptimmune Therapeutics plc (ADAP) a Buy, Sell, or Hold?
NASDAQ : ADAP
Adaptimmune Therapeutics plc
$0.0485 USD
$0.0 (-3.0%)
- Volume
- 1.68M
- Average Volume
- 110.64M
- Market Capitalization
- $75.16M
- P/E Ratio
- -0.16
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $0.86
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.52
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Adrian G. Rawcliffe |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADAP |
| CUSIP | 00653A107 |
| CIK | 0001621227 |
| Web | https://www.adaptimmune.com |
| Phone | 44 12 3543 0000 |
| Currency | USD |
| Employees | 506 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | -0.69 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.52 |
| Quick Ratio | 1.29 |
| Cash Ratio | 0.51 |
Sales & Book Value
| Annual Sales | $178.03M |
| Price / Sales | 3.59 |
| Cash Flow | -0.38 |
| Price / Cash Flow | -0.74 |
| Price / Book | -0.18 |
Price Target and Rating
| Average Stock Price Forecast | $3.00 |
| High Stock Price Forecast | $4.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | -98.38% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.28 |
| Trailing P/E Ratio | -0.16 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | -$70.81M |
| Net Margin | -371.74% |
| Pretax Margin | -366.08% |
| Return on Equity | 143.79% |
| Return on Assets | -59.65% |
Financials Score
| AltmanZ Score | -15.64 |
| Piotroski Score | 0.00 |
| Working Capital | 26.6M |
| Total Assets | 130.63M |
| Ebit | -160.38M |
| Market Cap | 75.16M |
| Total Liabilities | 201.59M |
Poll Results
About Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets. The company's pipeline features several key candidates: ADP-A2M4 is in advanced clinical development, with Phase II trials underway for synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1), as well as for head and neck cancer (SPEARHEAD-2). Additionally, it is undergoing Phase I assessment for a wide range of cancers, including urothelial, melanoma, head and neck, ovarian, non-small cell lung, esoph ... ageal, gastric, synovial sarcoma, and MRCLS. ADP-A2AFP is currently in Phase I clinical trials for hepatocellular carcinoma. ADP-A2M4CD8, which utilizes SPEAR T-cells, is also in Phase I trials for treating lung, gastroesophageal, head and neck, ovarian, and bladder cancers. Adaptimmune has established a diverse portfolio of strategic collaborations, including a licensing and partnership agreement with GSK, and third-party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and the National Center for Cancer Immune Therapy in Denmark. Further alliances include a strategic agreement with the MD Anderson Cancer Center and a co-development and co-commercialization agreement with Universal Cells, Inc. A significant strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd focuses on advancing personalized allogeneic T-cell therapies using aß T-cell receptors. Founded in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
2026-06-29 06:45:00
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.
Frequently Asked Questions
-
What is the current Adaptimmune Therapeutics plc (ADAP) stock price?
-
Adaptimmune Therapeutics plc(NASDAQ:ADAP) stock price is $0.0485 in the last trading session. During the trading session, ADAP stock reached the peak price of $0.86 while $0.0202 was the lowest point it dropped to. The percentage change in ADAP stock occurred in the recent session was --3.0% while the dollar amount for the price change in ADAP stock was -$0.0.
-
ADAP's industry and sector of operation?
-
The NASDAQ listed ADAP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADAP?
-
John Lunger | Chief Patient Supply Officer
Joanna Brewer | Chief Scientific Officer
Dana Lynch | Senior Director of Corporate Communications
Elliot Norry | Chief Medical Officer
Juli Miller | Vice President of Corporate Affairs & Investor Relations -
How many employees does ADAP have?
-
Number of ADAP employees currently stands at 506. ADAP operates from 60 Jubilee Avenue, Abingdon, None OX14 4RX, GB.
-
Link for ADAP official website?
-
Official Website of ADAP is: https://www.adaptimmune.com
-
How do I contact ADAP?
-
ADAP could be contacted at phone #44 12 3543 0000 and can also be accessed through its website. ADAP operates from 60 Jubilee Avenue, Abingdon, None OX14 4RX, GB.
-
How many shares of ADAP are traded daily?
-
The average number of ADAP shares traded daily for last 3 months was 110.64M.
-
What is the market cap of ADAP currently?
-
The market value of ADAP currently stands at $75.16M with its latest stock price at $0.0485